Diana Crivellari

TL;DR: In premenopausal women with hormone-receptor-positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppressed, significantly reduced recurrence.

TL;DR: Using data from 9524 women with early breast cancer who were randomized in International Breast Cancer Study Group clinical trials between 1978 and 1999, a group at sufficient risk to justify routine screening for occult central nervous system metastases was not defined.

TL;DR: Avoiding axillary clearance for women ≥ 60 years old who have clinically N0 disease and receive Tam results in similar efficacy with improved QL, with the largest differences observed from baseline to post-operative, with patients randomized to Sx+Ax having worse QL and more side effects.

TL;DR: The findings of the IBCSG 23-01 trial corroborate those obtained at 5 years and are consistent with those of the 10-year follow-up analysis of the Z0011 trial, and support the current practice of not doing an axillary dissection when the tumour burden in the sentinel nodes is minimal or moderate.

TL;DR: The endocrine effects of chemotherapy alone are insufficient for the younger age group and these patients should strongly consider additional endocrine therapies (tamoxifen or ovarian ablation) if their tumours express oestrogen receptors.